临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 2653994-08-0

Opnurasib (JDQ-443)

中文名称:2-丙烯-1-酮, 1-[6-[(4R)-4-(5-氯-6-甲基-1H-吭唑-4-基)-5-甲基-3-(1-甲基-1H-吭哌醇-5-基)-1H-吡哧醇-1-酰基]-2-阿唑酮[3.3]庚-2-基]-
CAS号:2653994-08-0
分子式: C29H28CIN7O 分子量: 526.03
产品形式: free base
研发状态: Recruiting
研发用途: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: December 6 2022
研发阶段: Phase 2
Opnurasib (JDQ-443,NVP-JDQ443) , a potent and selective, orally bioavailable covalent inhibitor of GDP-bound KRAS^G12C with an IC50 of 0.012 µM for inhibition of c-Raf recruitment.

CAS: 265121-04-8

Fosaprepitant dimeglumine salt

中文名称:福沙匹坦二甲葡胺
CAS号:265121-04-8
分子式: C23H22F7N4O6P.2C7H17NO5 分子量: 1004.83
产品形式: dimeglumine salt
研发状态: Recruiting
研发用途: Neoplasms
研究机构: Xijing Hospital
研发日期: July 15 2022
研发阶段: Not Applicable
Fosaprepitant dimeglumine salt (MK-0517) is a water-soluble phosphoryl prodrug for Aprepitant which is a NK1 antagonist.

CAS: 2649788-46-3

LY3537982 (KRAS G12C inhibitor 19)

CAS号:2649788-46-3
分子式: C25H19ClF2N4O3S 分子量: 528.96
产品形式: free base
研发状态: Recruiting
研发用途: Advanced Solid Tumors
研究机构: Eli Lilly and Company
研发日期: February 29 2024
研发阶段: Phase 1
LY3537982 (KRAS G12C inhibitor 19) is a highly selective and potent inhibitor of the KRAS-G12C protein. LY3537982 selectively inhibits the growth of KRAS G12C mutant cells H23 G12C, H358 G12C, and H2122 G12C with IC50s of 1.04 nM, 1.16 nM, and 11.38 nM, respectively.

CAS: 2647442-33-7(free base)

VV116

CAS号:2647442-33-7(free base)
分子式: C24H30DN5O7 分子量: 502.54
产品形式: Free base
研发状态: Completed
研发用途: Subjects With Liver Function Injury; Normal Liver Function Subject
研究机构: Shanghai Vinnerna Biosciences Co. Ltd.; Sponsor GmbH
研发日期: July 28 2023
研发阶段: Phase 1
VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.

CAS: 2639957-39-2

Exarafenib

CAS号:2639957-39-2
分子式: C26H34F3N5O3 分子量: 521.58
产品形式: free base
研发状态: Recruiting
研发用途: Solid Tumor Adult; Non-small Cell Lung Cancer; Melanoma
研究机构: Kinnate Biopharma
研发日期: August 4 2021
研发阶段: Phase 1
Exarafenib(KIN-002787, KIN-2787, RAF/KIN_2787) is an orally-available, selective inhibitor of pan-RAF. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. KIN-2787 exhibits low nanomolar to picomolar potency against RAF1, BRAF, and ARAF with an IC50 of 0.06-3.46 nM with minimal activity towards non-RAF kinases.

CAS: 2628280-40-8

Nirmatrelvir (PF-07321332)

中文名称:帕罗韦德
CAS号:2628280-40-8
分子式: C23H32F3N5O4 分子量: 499.53
产品形式: Free base
研发状态: Terminated
研发用途: COVID-19
研究机构: Pfizer
研发日期: September 7 2022
研发阶段: Phase 1
Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (Mpro, also referred to as 3CL protease) with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme.